Background. This study aimed to elucidate predictors of liver fibrosis in patients with chronic hepatitis B virus (HBV) infection. Methods. Transient elastography was performed to define liver stiffness in 533 patients with chronic HBV infection (mean age ± standard deviation, 30.72 ± 0.57 years). Protein array was performed on serum samples and lysates of Huh7 cells transfected with HBV mutants; the results were confirmed by enzyme-linked immunosorbent assay. Single-nucleotide polymorphisms in the gene encoding interleukin 1β (IL-1β) were examined in patients with chronic HBV infection with and without liver fibrosis.
Chronic hepatitis B virus (HBV) infection remains the leading cause of liver cirrhosis and hepatocellular carcinoma globally [1, 2] . During chronic HBV infection, HBV e antigen (HBeAg) seroconversion generally indicates reduce viral replication, but the majority of liver cirrhosis occurs after HBeAg seroconversion [3, 4] . Liver biopsy is the gold standard for detection of liver fibrosis in subjects with chronic HBV infection, but is painful and invasive. The aspartate transaminase (AST) to platelet ratio index (APRI) and fibrosis 4 scoring system (FIB-4) were developed as clinical noninvasive predictors of liver fibrosis, but their sensitivity and specificity are insufficient [5] [6] [7] . Liver stiffness measurement (LSM) by transient elastography (TE) is noninvasive, does not involve radiation, and can be performed repeatedly [8] [9] [10] [11] [12] . LSM has been extensively validated in subjects with chronic HBV infection, and LSM findings correlate well with METAVIR fibrosis scores graded in biopsy tissue specimens [8] [9] [10] [11] [12] .
HBeAg-negative hepatitis is predictive of liver cirrhosis during chronic HBV infection [3] . Subjects with HBeAgnegative hepatitis have a higher frequency of A1762T/G1764A, C2063A, and A2131C HBV gene mutations than those without HBeAg-negative hepatitis [13] . The roles of these identified mutants in liver fibrosis remain unclear.
The host immune response plays a role in liver damage and disease progression [14] [15] [16] [17] [18] [19] [20] . However, none of these studies assessed HBV mutant strains, serum biomarkers, and the course of liver fibrosis from childhood to adulthood. We aimed to elucidate the prevalence and long-term progression of liver fibrosis in subjects with chronic HBV infection from childhood to adulthood, and its predictors.
METHODS

Study Subjects and Clinical Data
We recruited 533 subjects with chronic HBV infection (264 male patients and 269 female patients) from the Department of Pediatrics of National Taiwan University Hospital (NTUH) and Taipei Veterans General Hospital (TVGH). They were followed beginning at a mean age (±SD) of 13.44 ± 0.58 years for a mean duration (±SD) of 17.27 ± 0.53 years, for a total of 9205 person-years of observation.
A detailed physical examination, abdominal sonography, and measurements of serum alanine aminotransferase (ALT) levels, α-fetoprotein levels, and HBV seromarkers (HBV surface antigen [HBsAg] , antibody against HBsAg [anti-HBs], antibody against HBV core antigen [anti-HBc], HBeAg, and antibody against HBeAg [anti-HBe]) were performed during the follow-up. Upon M A J O R A R T I C L E detection of elevated serum ALT levels, the follow-up interval was shortened to 1-3 months. Subjects with hepatitis C virus coinfection were excluded. We did not assess anti-hepatitis D virus (HDV), owing to the low prevalence in Taiwan [21] .
The upper limit of normal for the ALT level was defined as 30 IU/L in Taiwan [22] . HBeAg-negative hepatitis was defined according to criteria of the Asian Pacific Association for the Study of the Liver [23] . The study protocol was approved by the institutional review boards of both the TVGH and the NTUH, and the patients or their guardians provided signed informed consent for collection of blood samples and clinical data.
HBV Marker Serological Tests, Determination of HBV DNA Loads, and
Genotyping
At each visit, serum samples were collected from patients with chronic HBV infection to examine HBV markers and liver function profiles. HBV markers (HBsAg, HBeAg, anti-HBs, antiHBe, and anti-HBc) were assessed by enzyme immunoassay (Abbott Laboratories, North Chicago, IL). HBV DNA load and genotype were analyzed in serum samples from subjects before HBeAg seroconversion using real-time polymerase chain reaction (PCR) and melt curve assays.
LSM and Controlled Attenuation Parameter (CAP) by TE
The LSM and CAP analysis of the liver were assessed by TE (FibroScan 502 touch; Echosense, Paris, France). LSM and CAP analysis were used to quantify the severity of liver fibrosis and steatosis, respectively [24, 25] . We performed TE and abdominal sonography at the same time, with patients having fasted for at least 6-hour period before examination. TE was performed every year beginning in January 2016 in the cohort, and 408 patients (76.55%) underwent the second TE during the study period.
Ten shots were performed within 3-5 minutes in each patient, and an interquartile range (IQR) over median ratio <0.3 per measurement was considered valid. The S, M, and XL probes were used in this study. Children with a thorax circumference of <75 cm were examined by the S probe (5 MHz), whereas children with a thorax circumference of >75 cm and adults were measured by the M probe (3.5 mHz) or XL probe (2.5 mHz), as appropriate. An LSM of 2.5-7 kPa was graded as absent or mild fibrosis (METAVIR fibrosis scores F0 and F1), 7-12.5 kPa was graded as significant or severe liver fibrosis (F2-F3), and >12.5 kPa was graded as liver cirrhosis (METAVIR fibrosis score F4), according to the criteria of Castera et al [24] . The sensitivity and specificity of TE for METAVIR fibrosis scores F2-F4 are 70% and 84%, respectively, according to a meta-analysis [26] . The APRI and FIB-4 score of the subjects were also calculated. Since interpretation of LSM data must be based on serum ALT levels at the time of TE [27] , none of the study subjects received antiviral agents before the analysis. All serum ALT levels were <80 IU/L at the time of TE.
Levels of Serum Fibrosis-Related Proteins in Subjects With Chronic HBV
Infection, With or Without Liver Fibrosis
Serum markers of fibrosis were evaluated using a protein array (C-series Human Antibody Array 4000 kit; RayBiotech) for 2 subjects with chronic HBV infection (1 male and 1 female patient aged 32 and 36 years, respectively) with LSMs of >12.5 kPa and for 2 subjects with chronic HBV infection with LSMs of <7 kPa (1 male and 1 female patient aged 35 and 37 years, respectively) in a matched design. All 4 subjects had normal serum ALT levels and did not receive antiviral agents before TE measurement.
Enzyme-Linked Immunosorbent Assay (ELISA) of Serum Levels of Fibrosis
Markers
The stored serum samples of 20 patients (mean age [±SD], 31.57 ± 2.05 years; male sex, 11; and HBV genotypes B and C, 12 and 8, respectively) with LSMs of >12.5 kPa and those of 20 subjects (mean age [±SD], 36.40 ± 2.36 years; male sex, 12; HBV genotypes B and C, 13 and 7, respectively) with LSMs of <7 kPa were analyzed by ELISA (DuoSet; R&D Systems, Minneapolis, MN) to confirm the cytokine array findings. All 40 subjects had normal serum ALT levels and did not received antiviral agents before TE.
Generation of HBeAg-Negative Hepatitis-Related Mutant Clones by Site-
Directed Mutagenesis
A1972T/G1764A, C2063A, and A2131C HBV mutants were reported by us to be associated with HBeAg-negative hepatitis [14] . Wild-type HBV DNA core/precore gene expression constructs and a 1.5× full-length genotype Ba HBV clone (clone B6) were amplified by PCR. These PCR products were cloned into the pCR2.1-TOPO vector (Invitrogen) as templates for PCR-mediated site-directed mutagenesis.
We selected the HBV precore/core gene mutants significantly associated with HBeAg-negative hepatitis and liver fibrosis as candidate targets for point mutagenesis, using the QuikChange Lightning Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA). The primers for point mutagenesis were designed using QuikChange primer design software (available at: http://www.stratagene.com/sdmdesigner/default.aspx), and PCR was conducted with the Pfu Turbo DNA polymerase (Stratagene, La Jolla, CA), followed by digestion for 16 hours with Dpn1 (New England BioLabs, Ipswich, MA) to remove the parental DNA template. The vector DNA was then transformed into competent cells, and the resulting single colonies were selected. All DNA constructs were sequenced to confirm the presence of the desired mutations.
Huh7 Hepatoma Cell Line Culture and Transfection
Huh7 cells were purchased from the Bioresource Collection and Research Center. Cell culture medium and fetal bovine serum (FBS; Invitrogen) were from Thermo Scientific (Logan, UT). Transfection into Huh7 cells (wild-type and mutant full-length HBV core/precore gene expression constructs and the B6 clone) was performed using GenJet DNA In Vitro Transfection Reagent (version II; SignaGen, Rockville, MD). A control vector was used for standardization and confirmation of transfection efficiency. The wild-type and mutant HBV B6 clones were next transfected into Huh7 cells. After transfection for 2 days, the Huh7 cells were lysed and subjected to cytokine antibody array and quantitative reverse-transcription PCR analysis.
Cytokine Antibody Arrays
The C-series Human Antibody Array 4000 kit (RayBiotech) was used to assess cytokine levels in cell lysates following the procedures recommended by the manufacturer. Briefly, the array membranes were incubated in blocking buffer for 30 minutes. After removing blocking buffer, the samples (250 μg of lysate diluted at least 10-fold with 1× blocking buffer) were added to the array membranes and incubated for 2 hours at room temperature. After incubation, the membranes were washed 3 times with Wash Buffer I and 2 times with Wash Buffer II for 5 minutes each. Biotin-conjugated antibodies were next added and incubated at room temperature for 2 hours. After washing membranes as directed in previous steps, 1000-fold diluted horseradish peroxidase-conjugated streptavidin was added, and the arrays were incubated at room temperature for 1 hour. The membranes were washed, and detection was performed with an enhanced chemiluminescence detection agent (Advansta). Each spot on the images was measured using ImageJ software (National Institutes of Health, Bethesda, MD).
DNA Extraction and Single-Nucleotide Polymorphism (SNP) Genotyping
One hundred and eighty-six subjects with chronic HBV infection (103 male patients and 83 female patients) >30 years of age were included in the SNP analysis (Supplementary Table 1 ). Genomic DNA was extracted from venous blood, using the Puregene kit (Gentra Systems, Minneapolis, MN) in accordance with the manufacturer's instructions. The -511 (rs16944) and -31 (rs1143627) positions in the promoter region of IL1B were identified using GenBank and a Japanese and Han Chinese SNP database, at an r 2 threshold of 0.8 with a minor allele frequency of >0.1. SNP genotyping was performed as described previously [14] .
Statistical Analysis
The Stata software package (version 14; StataCorp, College Station, TX) was used for analyses. The Student t test or MannWhitney U test were used to evaluate differences in continuous variables between the 2 groups. The Fisher exact test or the χ 2 test were used to assess differences between the groups. Receiver operating characteristic curve analysis was used to determine the cutoff. Logistic regression was used to assess the odds of binary outcomes (LSM <7 or ≥7 kPa) for each predictive value. All SNPs were assessed for Hardy-Weinberg equilibrium, using the χ 2 test. Linkage disequilibrium was also assessed in these 2 SNPs. The Bonferroni correction was used to adjust P values for multiple comparisons.
RESULTS
General Characteristics
The 533 subjects with chronic HBV infection underwent TE at a mean age of 30.72 years (95% CI, 29.60-31.83 years), and their mean LSM was 5.38 kPa (95% CI, 5.16-5.60 kPa). The mean ALT level was 32.68 IU/L (95% CI, 26.90-38.46 IU/L), and the mean CAP was 227.66 dB/m (95% CI, 222.33-232.99 dB/m). The subjects were followed beginning at a mean age of 13.44 years; the majority (449 [84.24%]) were HBeAg positive at the first medical visit, and 186 (34.90%) remained HBeAg positive at the time of the TE. Twenty-two subjects (4.13%) in this cohort had HBeAg-negative hepatitis before the TE. In total, 374 subjects (70.17%) underwent a platelet count at the time of TE. The mean APRI was 0.38 (95% CI, .27-.50), and the mean FIB-4 score was 0.74 (95% CI, .68-.80; Table 1 ). There were 408 subjects (76.55%) underwent a second TE 1 year after the first test, and there was no obvious difference between the first and second TE measurement (mean [±SD], 5.45 ± 3.08 and 5.25 ± 2.85 kPa, respectively; P = .06). Three patients received a diagnosis of hepatocellular carcinoma during follow-up, all of whom underwent total tumor resection before TE. Their LSM were 3.6, 5.3, and 30.9 kPa, respectively, at the time of TE. During the follow-up period, 106 subjects experienced severe, protracted inflammation and received antiviral therapy according to the guidelines of the National Health Insurance Administration of Taiwan. The antivirals used prior to the TE study comprised interferon alfa (for 32 subjects), lamivudine (for 23), entecavir (for 46), and tenofovir disoproxil fumarate (for 5). All subjects completed their course of antiviral therapy at least 6 months before TE.
Predictors of Liver Stiffness
Receiver operating characteristic curve analysis yielded a serum α-fetoprotein cutoff level of >3.6 ng/mL for predicting an LSM of ≥7 kPa in patients with chronic HBV infection (sensitivity, 42.6%; specificity, 85.1%). A cutoff age of ≥18 years at TE was most predictive of an LSM of ≥7 kPa (sensitivity, 92.6%; specificity, 20.2%).
LSMs were higher in male subjects, those with a serum α-fetoprotein level of >3.6 ng/mL, and subjects ≥18 years of age (P <.0001, <.0001, and .005, respectively) in both the whole cohort (Supplementary Table 2 ) and the initially HBeAgpositive subcohort (Table 2) . HBV genotype, HBeAg, and HBsAg status at TE were not significantly associated with LSMs (Table 2 and Supplementary Table 2) .
Male sex, a serum α-fetoprotein level of >3.6 ng/mL, and age ≥18 years were independent predictors of an LSM of ≥7 kPa (METAVIR fibrosis scores F2-F4) in univariate and multivariate logistic regression analyses (Table 3) .
Progression of Liver Fibrosis After HBeAg Seroconversion
In the full cohort, 84 subjects were negative for HBeAg and 449 were positive for HBeAg at the first medical visit. Among the 449 initially HBeAg-positive subjects, 264 developed HBeAg seroconversion during a mean follow-up period of 22.56 years (95% CI, 21.24-23.88 years). In total, 22 subjects developed HBeAg-negative hepatitis after their HBeAg seroconversion, and 242 without HBeAg-negative hepatitis had higher LSMs after HBeAg seroconversion (mean [± SE], 6.50 ± 0.69 vs 5.10 ± 0.11 kPa; P = .001). This phenomenon was also consistent in the whole cohort, with LSMs among 326 patients without HBeAg-negative hepatitis less than those 22 with HBeAg-negative hepatitis after HBeAg-seroconversion (mean LSM [±SD], 5.09 ± 0.09 vs 6.50 ± 0.69 kPa; P < .001).
In 374 subjects with available platelet counts at the time of TE, we analyzed the relationship between the APRI, FIB-4 score, and LSM. Subjects with LSMs ≥7 kPa (n = 42) had a higher APRI (mean ±SD, 1.00 ± 0.50 vs 0.31 ± 0.01; P = .0001) and FIB-4 score (1.04 ± 0.16 vs 0.70 ± 0.03; P = .0003) than those with LSMs of <7 kPa (n = 332). Abbreviations: ARV, antiviral therapy; CI, confidence interval; SE, standard error; TE, transient elastography.
a A P value of <.008 was considered statistically significant, and a P value of .008-.016 after Bonferroni correction was indicative of a trend.
b HBV genotype data were available for 426 initially HBeAg-positive and HBsAg-positive subjects with chronic HBV infection.
Serum Liver Fibrosis Biomarkers
The serum protein profile differed significantly between 2 subjects with chronic HBV infection with LSMs of >12. Figure 1) .
HBeAg-Negative Hepatitis Mutants and Liver Fibrosis
HBeAg-negative hepatitis was associated with increased liver stiffness after HBeAg seroconversion. We assessed the impact of HBeAg-negative hepatitis-associated mutants (A1972T/ G1764A, C2063A, and A2131C) on changes in the cytokine profile. The IL-1β level was elevated in the lysate of Huh7 cells transfected with HBeAg-negative hepatitis mutants (A1972T/ G1764A, C2063A, and A2131C; Figure 2 ).
IL1B SNPs
Age is a key risk factor for liver fibrosis during chronic HBV infection. We analyzed the rs1143627 and rs16944 SNP sites in the gene encoding IL-1β in 186 patients with chronic HBV Table 3) .
The haplotype analysis showed higher LSMs in subjects with the AA/CC haplotype at rs16944/rs1143627 (-511/-31[ n = 32) than in others (mean ± SD, 5.94 ± 0.37 vs 5.18 ± 0.16 kPa; P < .01). The serum IL-1β levels in the 26 subjects with rs1143627 and rs16944 SNPs were then determined (14 male patients; mean ± SD, 36.96 ± 1.09 years; 17 with genotype B and 9 with genotype C). Four subjects had the AA/CC haplotype at the rs16944/rs1143627 SNP site, all of whom had higher serum IL-1β levels than 22 subjects with the G allele at rs16944 and the T allele at rs1143627 (mean ± SD, 35.48 ± 17.04 vs 15.00 ± 5.46 ng/mL; P = .03).
DISCUSSION
Liver fibrosis is an indicator of poor clinical outcomes but is difficult to define during the early stage of chronic HBV infection. In a large cohort followed since childhood, we demonstrated that LSMs in subjects with chronic HBV infection increased significantly beyond childhood. Our previous studies showed HBeAg seroconversion after 18 years of age significantly increases the risk of HBeAg-negative hepatitis after HBeAg seroconversion [13, 28] . The damage to liver parenchyma and the progression of liver fibrosis and stiffness begin in childhood in the presence of chronic HBV infection. These findings suggest the importance of aggressive management of HBeAg-positive children to achieve earlier HBeAg seroconversion, if the patient has a clinical indication for antiviral therapy and the therapy is effective. Early, noninvasive, and precise monitoring of liver damage and the progression of liver fibrosis in patients with chronic HBV infection may be necessary. The serum α-fetoprotein level was closely correlated with liver stiffness, assessed by TE, in this study. Moreover, a serum α-fetoprotein level >3.6 ng/mL was predictive of an LSM of ≥7 kPa. α-fetoprotein levels have been reported to increase with increasing severity of inflammation and fibrosis in patients with chronic hepatitis, and these findings are supported by our data [29, 30] .
Animal studies have shown that androgens increase HBV gene transcription, which is repressed by the estrogen pathway [31] [32] [33] . Serum testosterone levels in male patients with chronic HBV infection were also associated with the severity of hepatitis [34] . Increased liver fibrosis in male patients with chronic HBV infection may be associated with androgen-pathway-mediated viral activation and liver damage.
Increasing evidence has demonstrated the role of the host immune response in the clinical course and outcome of chronic HBV infection. Previous studies reported a relationship between the progression of liver fibrosis with TGF-β1, TNF-α, IL-1β, interleukin 10, interleukin 12, interleukin 17, interleukin 22, interleukin 27, angiotensin II, and leptin levels in hepatitis C virus infection, alcohol-induced liver cirrhosis, nonalcoholic steatohepatitis, and primary biliary cirrhosis [35] [36] [37] . These serum markers are associated with activation of profibrogenic macrophages in the liver [19, 20] . IL-1β is an upstream proinflammatory cytokine that activates profibrogenic M1 macrophages and promotes the survival of activated hepatic stellate cell-derived myofibroblasts [19] . Activated myofibroblasts then secrete extracellular matrix to induce the liver fibrogenic M1 macrophage pathway and release tissue inhibitor of metalloproteinase to suppress the MMP-mediated fibrolytic M2 macrophage pathway [20] . These reports support the findings of our study: upregulation of the M1 profibrogenic macrophage pathway (IL-1β and MCP-3) and downregulation of the M2 fibrolytic macrophage pathway (MMP-9) in subjects with METAVIR fibrosis score F4 liver fibrosis. The occurrence of HBeAg-negative hepatitis is associated with increased liver fibrosis after HBeAg seroconversion, and IL-1β was upregulated in hepatoma cells transfected with HBV mutants associated with HBeAg-negative hepatitis in this study. Since the IL-1β level is elevated in both the serum of patients with liver cirrhosis and hepatocytes transfected with mutant strains involved in HBeAg-negative hepatitis, we analyzed IL1B gene polymorphisms in the promoter region in patients with chronic HBV infection aged >30 years. The AA genotype at rs16944 and the CC genotype at rs1143627, located in the promoter region of IL1B, were associated with liver fibrosis in subjects with chronic HBV infection >30 years of age. The haplotype analysis showed that the AA/CC haplotype at the -511/-31 (rs16944/ rs1143627) locus in IL1B is associated with higher serum IL-1β levels and liver fibrosis.
This study had some limitations. We did not observe a relationship between antiviral therapy and liver fibrosis in this study. This may be due in part to inadequate statistical power, owing to the small number of patients who received antiviral therapy.
Alternatively, patients who need antiviral agents may be more prone to inflammation than those who do not require antiviral agents. The mean CAP of the study cohort was 227.66 dB/m (95% CI, 222.33-232.99 dB/m), which is below the reported cutoff for significant steatohepatitis [25, 38] . Hence, steatohepatitis was not a significant confounding factor that increased liver stiffness values in our cohort.
In conclusion, we evaluated the risk factors for liver fibrosis in patients with chronic HBV infection. Male sex, age >18 years, elevated α-fetoprotein level, and HBeAg-negative hepatitis were risk factors for liver fibrosis. IL-1β is important for the progression of liver fibrosis during chronic HBV infection.
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